McRISC, Inc.

Founded: 2018
1-2 employees
Stage: Prototype/ MVP
Substance misuse contributes to 638,000 yearly deaths in the U.S., almost 200 daily drug overdoses. There is no accessible, simple means to assess addiction risk or determine the best treatment for those struggling with Substance Use Disorders. (SUD). McRISC© offers the first and only acute and chronic illness-driven substance use assessment, prevention and treatment guidance for healthcare providers. It’s online and takes 10 minutes. McRISC© does the following to help end the opioid epidemic: Predicts addiction risk to help prevent it Provides treatment guidance based on the most current research Gets people to the right treatment at the right time Offers healthcare providers and criminal justice reform efficient research-based guidance. Its database will create an unprecedented resource for further SUD research. Our mission is to de-stigmatize SUD, prevent substance addictions, optimize treatment for sustained remission, reduce substance-related costs, and save lives.
Projects Created
Substance Use Assessment
Diagnostics, Risk Factors, Recovery Capital
0
MedStartr
Index Score
McRISC© offers the first and only acute and chronic illness-driven substance use assessment, prevention and treatment guidance for healthcare and other providers.
Chicago, United States
 100  pledged of  10,000 goal
  • 5 Likes
  • Partner
  • Mentor
  • This campaign has ended but you can still get involved.
Company Contacts
Address:

1230 - 222 W Merchandise Mart Plaza

Chicago,

US 60654

Website URL:
Connect With Us
Contact Person

Important Disclosure: MedStartr.com is a website owned and operated by MedStartr, Inc., which is not a broker-dealer, funding portal or investment advisor; and neither the website nor MedStartr, Inc. participate in the offer or sale of securities. All securities related activity is conducted through Young America Capital, LLC, a registered broker-dealer and member of FINRA/SIPC. No communication, through this website, email or in any other medium, should be construed as a recommendation for any securities offering.